Abstract：Objective To investigate the clinical effect of drug-loaded microspheres transcatheter arterial chemoembolization (DEB-TACE) treating large liver cancer.Methods A retrospective analysis of 73 cases of large liver cancer patients undergoing transarterial arterial chemoembolization admitted to our hospital from January 2017 to January 2019,including 35 cases of drug-loaded microsphere hepatic arterial chemoembolization (DEB-TACE) (observation group),38 cases of traditional hepatic arterial chemoembolization (c-TACE) (control group), laboratory tests were performed before treatment and on days 3 and 7 after treatment, and intensive CT examination was performed before treatment and 1 month after treatment.The imaging data and clinical data were analyzed and summarized to compare the differences in the incidence of tumor response, complications and adverse reactions between the two treatment methods in patients.Results The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of patients of the two groups on the 3rd and 7th days after treatment were higher than those in this group before treatment,and the differences were statistically significant(P＜0.05).There were no significant differences in ALT and AST between the two groups on the 3rd and 7th days after treatment (P＞0.05).There were no serious adverse reactions in both groups; there were no significant differences in the disease remission rate and disease control rate at 1 month after treatment between two groups (P＞0.05).Conclusion DEB-TACE is safe and effective in the treatment of large liver cancer, and it is worthy of clinical application.
京公网安备 11010502046607号